These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7935506)

  • 41. Peptide-induced antiviral protection by cytotoxic T cells.
    Schulz M; Zinkernagel RM; Hengartner H
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):991-3. PubMed ID: 1992491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.
    Tam JP; Lu YA
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9084-8. PubMed ID: 2480595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo.
    Sauzet JP; Moog C; Krivine A; Martinon F; Bossus M; Gras-Masse H; Tartar A; Guillet JG; Gomard E
    AIDS Res Hum Retroviruses; 1998 Jul; 14(10):901-9. PubMed ID: 9671219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24.
    Nishino Y; Kameoka M; Okada Y; Zhong Q; Kimura T; Azuma I; Ikuta K
    Vaccine; 1994 May; 12(6):485-91. PubMed ID: 7913566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design.
    Moreno R; Jiang L; Moehle K; Zurbriggen R; Glück R; Robinson JA; Pluschke G
    Chembiochem; 2001 Nov; 2(11):838-43. PubMed ID: 11948870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation.
    Sadler K; Zeng W; Jackson DC
    J Pept Res; 2002 Sep; 60(3):150-8. PubMed ID: 12213124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptide vaccines and peptide libraries.
    Wiesmüller KH; Fleckenstein B; Jung G
    Biol Chem; 2001 Apr; 382(4):571-9. PubMed ID: 11405221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
    Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
    Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of antibodies against the Plasmodium falciparum p126 antigen in non-responder H-2b and partial-responder H-2d mice using synthetic peptides.
    Gilardeau Truffinet M; Bossus M; Camus D; Delplace P; Mazingue C; Diesis E; Tartar A; Moreau S; Gras-Masse H; Banic DM
    Pept Res; 1996; 9(2):61-70. PubMed ID: 8738980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polarity of immunogens: implications for vaccine design.
    Golvano J; Lasarte JJ; Sarobe P; Gullón A; Prieto J; Borrás-Cuesta F
    Eur J Immunol; 1990 Oct; 20(10):2363-6. PubMed ID: 1700756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity.
    Zhu X; Ramos TV; Gras-Masse H; Kaplan BE; BenMohamed L
    Eur J Immunol; 2004 Nov; 34(11):3102-14. PubMed ID: 15368273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
    Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
    Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conformational study of a short Pertussis toxin T cell epitope incorporated in a multiple antigen peptide template by CD and two-dimensional NMR. Analysis of the structural effects on the activity of synthetic immunogens.
    Esposito G; Fogolari F; Viglino P; Cattarinussi S; De Magistris MT; Chiappinelli L; Pessi A
    Eur J Biochem; 1993 Oct; 217(1):171-87. PubMed ID: 7693460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.
    Zeng W; Ghosh S; Lau YF; Brown LE; Jackson DC
    J Immunol; 2002 Nov; 169(9):4905-12. PubMed ID: 12391202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.
    Sedlik C; Dadaglio G; Saron MF; Deriaud E; Rojas M; Casal SI; Leclerc C
    J Virol; 2000 Jul; 74(13):5769-75. PubMed ID: 10846055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop.
    Kameoka M; Nishino Y; Matsuo K; Ohara N; Kimura T; Yamazaki A; Yamada T; Ikuta K
    Vaccine; 1994 Feb; 12(2):153-8. PubMed ID: 8147098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.